

**26827**

## **Masitinib in severe asthma: Results from a randomized, phase 3 trial**

Severe asthma, Asthma - management, RCT (Randomized Controlled Trial)

**P. Chanez<sup>1</sup>, G. Ursol<sup>2</sup>, O. Korzh<sup>3</sup>, V. Deshmukh<sup>4</sup>, L. Kuryk<sup>5</sup>, N. Monja-Marie<sup>6</sup>, O. Godlevska<sup>3</sup>, G. Devouassoux<sup>7</sup>, E. Khodosh<sup>8</sup>, E. Israel<sup>9</sup>, C. Mansfield<sup>10</sup>, O. Hermine<sup>11</sup>, L. Davidescu<sup>12</sup>**

<sup>1</sup>Department of Respiratory Diseases, Aix-Marseille University - Marseille (France), <sup>2</sup>Medical and Diagnostic Center of Private Enterprise of Private Production Company "Acinus" - Kropyvnytskyi (Ukraine), <sup>3</sup>Department of General Practice - Family Medicine, Kharkiv Medical Academy of Postgraduate Education - Kharkiv (Ukraine), <sup>4</sup>Department of Pulmonary Medicine. Respira Hospital - Nagpur (India), <sup>5</sup>National Institute of Phthiology and Pulmonology named after F.G. Yanovsky of National Academy of Medical Sciences of Ukraine - Kiev (Ukraine), <sup>6</sup>Moriana Clinical Research - Brandfort (South Africa), <sup>7</sup>Department of Pulmonology, Hôpital de la Croix Rousse, GHN, HCL and Université Claude Bernard Lyon 1 - Lyon (France), <sup>8</sup>Department of Pulmonology, Municipal Nonprofit Enterprise, City Clinical Hospital #13 - Kharkiv (Ukraine), <sup>9</sup>Brigham and Women's Hospital - Boston (USA), <sup>10</sup>AB Science - Paris (France), <sup>11</sup>Imagine Institute, INSERM UMR 1163 and CNRS ERL 8254, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implication, Hôpital Necker - Paris (France), <sup>12</sup>Department of Pulmonology, University of Medicine and Pharmacy Oradea - Oradea (Romania)

### BACKGROUND:

Study AB07015 evaluated oral masitinib (6 mg/kg/d) in severe persistent asthma, uncontrolled by high-dose ICS/LABA and oral corticosteroids (OCS) ( $\geq 7.5$  mg/d), irrespective of baseline eosinophil levels.

### METHOD:

Eligible adult patients (pts) were treated for 36 weeks (with possible blinded extension until at least week-96). Primary endpoint was reduction of annualized severe asthma exacerbation rate (SAER) for overall exposure (W0–W96). A key subgroup was defined as pts with initial eosinophil count of  $\geq 150$  cells/ $\mu$ L (EOS). Subgroup analysis according to cumulative OCS intake was also performed, a higher dose indicating more severe asthma that is harder to control.

### RESULTS:

19/08/2020

MAS (n=240) showed a significant 35% reduction in SAER relative to placebo (PBO, n=115) with a rate ratio (RR) of 0.64 ([95%CI[0.47–0.90];p=0.0103]). For the EOS subgroup, MAS (n=181) showed a significant 38% reduction in SAER (n=87); RR=0.62 ([95%CI[0.42–0.91];p=0.0156). Benefit of MAS increased in pts who had a higher cumulated use of OCS (**see Table**). In pts receiving an annualized cumulative OCS intake of >1000 mg, SAER was significantly reduced by 51% in the primary analysis population (p=0.0060), and by 71% in the EOS subgroup (p=0.0003). Safety was consistent with the known MAS profile and no new safety signals were observed. Incidence of ≥1 adverse event was 83.4% for MAS vs 82.0% for PBO.

## CONCLUSION:

Masitinib demonstrated a positive benefit/risk ratio in uncontrolled severe asthma, regardless of baseline eosinophil level. Benefits were greatest in pts with the highest OCS dose dependency.

**Table: Analysis of severe asthma exacerbation rates (SAER) according to prior cumulative OCS intake**

Treatment group (n)	Exposure, mo	RR [95% CI]	Reduction	P-value
<i>Primary analysis population</i>				
<b>Cumulative OCS &gt;500 mg</b>				
Masitinib (161)	13.8	0.59 [0.39, 0.88]	41%	0.0092
Placebo (82)	14.4			
<b>Cumulative OCS &gt;1000 mg</b>				
Masitinib (120)	13.9	0.49 [0.29, 0.82]	51%	0.0060
Placebo (66)	15.2			
<b>Cumulative OCS &gt;1500 mg</b>				
Masitinib (89)	14.5	0.43 [0.21, 0.88]	57%	0.0203
Placebo (52)	15.2			
<i>EOS subgroup</i>				
<b>Cumulative OCS &gt;500 mg</b>				
Masitinib (127)	13.4	0.51 [0.39, 0.88]	49%	0.0049
Placebo (60)	13.9			
<b>Cumulative OCS &gt;1000 mg</b>				
Masitinib (92)	13.3	0.29 [0.29, 0.82]	71%	0.0003
Placebo (46)	15.2			
<b>Cumulative OCS &gt;1500 mg</b>				
Masitinib (69)	13.9	0.28 [0.21, 0.88]	72%	0.0032
Placebo (38)	15.5			

EOS subgroup: pts with a baseline eosinophil count of ≥150 cells/μL. OCS: oral corticosteroid (cumulative intake in the 12 months prior to screening); SAER: annualized severe asthma exacerbation rate. Severe exacerbation event defined as worsening asthma leading to an increase from stable maintenance dose of corticosteroids for ≥3 days or hospitalization.